The present study reports a case of *Leishmania*(*Leishmania*) *infantum* as an agent of cutaneous leishmaniasis (CL) in patients from the State of *Mato Grosso do Sul*(Brazil). This is the first description of CL in immunocompetent patients in Brazil.

The species *L. infantum* was first associated with CL in France, in 1980[@B01], where more autochtonous cases have been reported since then[@B01] ^,^ [@B02] ^,^ [@B03]. Since this first retrieval, several cases of CL have been reported in other Mediterranean countries[@B04] ^,^ [@B05] ^,^ [@B06] ^,^ [@B07] ^,^ [@B08]. Cutaneous leishmaniasis cases due to*L*. *infantum* are mainly reported in areas where the visceral disease is endemic.

In *Mato Grosso do Sul* ([Fig. 1](#f01){ref-type="fig"}), leishmaniasis is endemic and is a significant threat to public health[@B09] ^,^ [@B10], where 42.9 cases were reported per 100,000 inhabitants from 2010 to 2013 for visceral leishmaniasis (VL), and 21.6 cases per 100,000 inhabitantsfor CL in the same period. Despite the fact that *Leishmania*(*Leishmania*) *amazonensis* and*Leishmania* (*Viannia*) *braziliensis*have been detected in the human population[@B10] ^,^ [@B11] ^,^ [@B12], studies on the isolation of species that cause CL in the State are scarce.

Fig. 1- The State of *Mato Grosso do Sul* (MS) in Brazil

From 2010 to 2013, 52 slides from cutaneous tissue imprints following punch biopsy, stained by the Giemsa method, with positive diagnosis of CL by direct examination were retrospectively scraped using a sterile scalpel for removal of all the material, which was inserted in a polypropylene tubes of 1.5 ml. Then, 600 µL of Cell Lysis Solution was added, and this solution was subjected to DNA extraction with a commercial kit (Promega Wizard(r) Genomic DNA Purification), following the manufacturer\'s instructions.

The PCR reaction was performed as described by VOLPINI *et al.* [@B13] and DE ANDRADE *et al.* [@B14]. For amplification of the kinetoplast DNA of*Leishmania* sp., the following primers were used: A: 5\'-(C/G)(C/G)(G/C)CC(C/A)CTA T(T/A)TTACACCAACCCC 3\' and B: 5\'-GGGGAGGGGCGTTCTGCGAA-3\'. A fragment of 120 bp was obtained.

Afterwards, 43 samples were considered positive, and subjected to RFLP analysis, where the PCR product was incubated with 10 U of the enzyme *Hae* III for 4 hours at 37 °C[@B13]. In all the reactions, DNA of*L. braziliensis* (MHOM/BR/75/M2903), *L. infantum*(MHOM/BR/74/PP75), *L. amazonensis* (IFLA/BR/67/PH8), and negative controls were used. The DNA used as a positive control was obtained by washing parasites from a culture mass with PBS and a subsequent DNA extraction. A sample containing the reagents mixture with 5 µL of water, without DNA, was used as a negative control.

After the sample analysis, it was possible to characterize the species of*Leishmania,* in 40 patients, but in three cases the profile generated in RFLP was not conclusive. Thus, *Leishmania*(*Leishmania*) *infantum* was characterized in the lesions of seven patients with CL (17.5%) ([Fig. 2](#f02){ref-type="fig"}). Of these patients, only one had coinfection with HIV and VL and presented skin lesions. The other patients did not exhibit immunodepression or the associated visceral disease during the diagnosis and therapy.

Fig. 2- RFLP patterns obtained after *Hae* III digestion of kDNA amplicons. MM - molecular marker - 50 bp, 1 to 7 - analyzed samples, Lb - positive control of *L. braziliensis*, Li - positive control of *L. infantum*, La - positive control of *L. amazonensis.*

*Leishmania infantum* has been identified as a causative agent of CL in humans from the Mediterranean. In the Southeast of Europe, this is the only species that has been detected in autochthonous cases[@B05].

In France, a fairly comprehensive study examined all the cases of leishmaniasis in the country, from 2009 to 2012. At that time, of the 317 autochthonous cases of leishmaniasis, 39 (12.3%) were cases of CL and all of them due to *L. infantum* [@B02].

Cases of *L. infantum* as an etiological agent of CL have previously been described in the Americas[@B15] ^,^ [@B16] ^,^ [@B17] ^,^ [@B18]. In Brazil, this species was first reported in the cutaneous lesions of immunosupressed patients by OLIVEIRA NETO *et al.* [@B19]. However, in the State of *MatoGrosso do Sul*, this species has only been isolated in patients with VL[@B12] ^,^ [@B20].

The finding of *L. infantum* in lesions of patients with CL in*Mato Grosso do Sul* is expected, since there are several reports of the presence of this species causing this clinical manifestation in endemic areas for VL in the Old and New World, as already mentioned. The scarcity of molecular studies aimed at identifying the species involved in cases of CL in this area contributed to the fact that *L*. *infantum* have not been previously identified, so that CL cases for this etiology are probably underdiagnosed and certainly undernotified.

This is the first description of the participation of *L. infantum* as a causative agent of the disease in immunocompetent patients in Brazil.

The identification of *Leishmania* spp. in certain transmission foci, particularly in areas where different sympatric species occur is important since it will improve the epidemiological knowledge of this disease. In addition, it contributes to the adoption of control measures, improvement of prognosis, and selection of appropriate therapeutic protocols[@B21] ^,^ [@B22] ^,^ [@B23].

Besides the characterization of the species, the isoenzyme identification of circulating strains can provide important information about these dermotropics strains, as observed in different locations[@B24] ^,^ [@B25]. Further studies are required to isolate and characterize the different strains of *Leishmania* spp. that affect humans in *Mato Grosso do Sul*, and to gain a better understanding of their tropism for cutaneous areas.
